World Health Organization schema for thymoma classification: a retrospective analysis of 93 cases

田晓东; 张竞; 梁朝阳; 柳曦; 张涛; 郭俊唐; 刘慧峰; 周乃康

您当前的位置：

首页 >

文章列表页 >

World Health Organization schema for thymoma classification: a retrospective analysis of 93 cases

更新时间：2026-01-09

- World Health Organization schema for thymoma classification: a retrospective analysis of 93 cases
- Journal of Army Medical University Vol. 29, Issue 9, Pages: 801-802(2007)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R730.2;R736.3
- Published：2007
- 稿件说明：
移动端阅览
田晓东,张竞,梁朝阳,柳曦,张涛,郭俊唐,刘慧峰,周乃康.93例胸腺瘤按WHO组织分型结果回顾性分析[J].陆军军医大学学报(原第三军医大学学报),2007,29(09):801-802.

　TIAN Xiao-dong,ZHANG Jing,LIANG Chao-yang,LIU Xi,ZHANG Tao,GUO Jun-tang,LIU Hui-feng,ZHOU Nai-kang.World Health Organization schema for thymoma classification: a retrospective analysis of 93 cases[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(09):801-802.
田晓东,张竞,梁朝阳,柳曦,张涛,郭俊唐,刘慧峰,周乃康.93例胸腺瘤按WHO组织分型结果回顾性分析[J].陆军军医大学学报(原第三军医大学学报),2007,29(09):801-802. DOI：

　TIAN Xiao-dong,ZHANG Jing,LIANG Chao-yang,LIU Xi,ZHANG Tao,GUO Jun-tang,LIU Hui-feng,ZHOU Nai-kang.World Health Organization schema for thymoma classification: a retrospective analysis of 93 cases[J].J Amry Med Univ (J Third Mil Med Univ),2007,29(09):801-802. DOI：

摘要

目的探讨WHO胸腺瘤病理组织分型临床应用的意义。方法按新的WHO胸腺瘤组织分型标准对我科手术治疗的93例胸腺瘤进行了回顾性分析，总结本组病例的组织分型、Masaoka分期及预后。结果 93例胸腺瘤中，WHO组织分型的A、AB、 B1、B2、B3、C型分别有6例（6.45%）、28例（30.11%）、15例（16.13%）、22例（23.66%）、9例（9.68%）、8例（8.60%）；复合型5例（5.38%）。Masaoka分期Ⅰ、Ⅱ、Ⅲ、Ⅳa、Ⅳb期分别为45、23、14、9、2例。组织分型与分期有较高的相关性。随访病例中有6例复发，B2及以上分型占5例。结论 WHO胸腺瘤组织分型方案能较好地指导临床治疗和判断预后，有较高的临床应用价值。

Abstract

Objective To study the significance of World Health Organization (WHO) schema for thymoma classification in clinical application. Methods Ninety-three cases of thymoma were analyzed based on WHO schema for thymoma classification. The histological classification

Masaoka stage and prognosis of thymoma were studied. Results In 93 thymomas

of WHO histological classification

type A in 6 cases

type AB in 28

type B1 in 15

type B2 in 22

type B3 in 9

type C in 8

and combined in 5. Of Masaoka stage

stage Ⅰin 45 cases

stage Ⅱ in 23

stage Ⅲ in 14

stage Ⅳa in 9

stage Ⅳb in 2. The histological subtype closely correlated with Masaoka stage. Thymoma reoccurred in 6 cases

among whom 5 cases was of B2 or advanced subtype. Conclusion WHO schema can be well applied to instruct clinical treatment and predict prognosis of thymoma.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

A novel estrogen receptor expression stratification (low/moderate/high) based on Chinese population provides more accurate prognosis prediction for HR⁺/HER2^- early breast cancer patients

Immunosuppressive microenvironment of TGIF1-overexpressing gastric cancers and its clinical significance

Impact of molecular heterogeneity of NPM1 mutations on prognosis of acute myeloid leukemia: a clinical report of 86 cases

Association of 5-factor modified frailty index and controlling nutritional status score with overall survival in patients with unresectable hepatocellular carcinoma undergoing interventional therapy

Construction and validation of prediction model for cervical cancer recurrence based on systemic inflammation response index and clinicopathological parameters

Related Author

WANG Chengfang

ZHOU Yuqin

ZHANG Yanling

QI Xiaowei

ZHANG Yi

TONG Huyun

CHEN Xu

ZHANG Wenjie

Related Institution

Department of Breast and Thyroid Surgery， First Affiliated Hospital， Army Medical University （Third Military Medical University）

Department of Gastroenterology， Chongqing Hechuan District People’s Hospital

School of Medicine， Chongqing University

Chongqing Key Laboratory of Precision Prevention and Treatment for Digestive System Tumors， Department of Gastroenterology， Army Medical Center of PLA/Daping Hospital of Third Military Medical University

Department of Hematology, the First Hospital of Lanzhou University

⁰